PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsDesonide
Desonide
Desonide, Desowen, Tridesilon (desonide) is a small molecule pharmaceutical. Desonide was first approved as Tridesilon on 1982-01-01. It is used to treat facial dermatoses, foot dermatoses, hand dermatoses, inflammation, and leg dermatoses amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
skin and connective tissue diseasesD017437
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Desonide, Desowen (discontinued: Desonate, Desonide, Verdeso)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Desonide
Tradename
Company
Number
Date
Products
DESOWENGaldermaN-019048 RX1984-12-14
1 products
DESONIDEPadagisN-017010 RX1982-01-01
1 products, RLD, RS
DESONIDEPadagisN-017426 RX1982-01-01
1 products, RLD, RS
Show 2 discontinued
Acetic acid
+
glacial
+
Desonide
Tradename
Company
Number
Date
Products
TRIDESILONBayerN-017914 DISCN1982-01-01
1 products
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
desonateNew Drug Application2010-11-08
desonideANDA2024-10-30
desonide ointment, 0.05%ANDA2024-04-08
desowenANDA, New Drug Application2019-01-28
lokaraANDA2013-11-22
tridesilon creamNew Drug Application2016-04-21
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
inflammationMP_0001845D007249—
facial dermatoses—D005148—
foot dermatoses—D005533—
hand dermatoses—D006229—
scalp dermatoses—D012536—
leg dermatoses—D007868—
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Desonide, Verdeso, Almirall
84606412027-08-13DPU-1412
89620002025-08-31DPU-1412
94923842025-08-31DPU-1412
ATC Codes
D: Dermatologicals
— D07: Corticosteroids, dermatological preparations
— D07A: Corticosteroid dermatological preparations, plain
— D07AB: Corticosteroids, moderately potent (group ii)
— D07AB08: Desonide
— D07B: Corticosteroids, combinations with antiseptics
— D07BB: Corticosteroids, moderately potent, combinations with antiseptics
— D07BB02: Desonide and antiseptics
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01B: Antiinflammatory agents, ophthalmologic
— S01BA: Corticosteroid ophthalmologic antiinflammatory agents, plain
— S01BA11: Desonide
HCPCS
Code
Description
J7626
Budesonide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, up to 0.5 mg
J7627
Budesonide, inhalation solution, compounded product, administered through dme, unit dose form, up to 0.5 mg
J7633
Budesonide, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, per 0.25 milligram
J7634
Budesonide, inhalation solution, compounded product, administered through dme, concentrated form, per 0.25 milligram
Clinical
Clinical Trials
12 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Atopic dermatitisD003876EFO_0000274L20——43—7
EczemaD004485HP_0000964L30.9——43—7
DermatitisD003872HP_0011123L30.9——43—7
PsoriasisD011565EFO_0000676L40———1—1
HyperpigmentationD017495HP_0000953————1—1
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———1————1
VasoconstrictionD014661——1————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Skin diseasesD012871—L00-L99————11
Skin agingD015595EFO_0005422—————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDesonide
INNdesonide
Description
Desonide (INN) is a low-potency topical corticosteroid anti-inflammatory that has been available since the 1970s. It is primarily used to treat atopic dermatitis (eczema), seborrheic dermatitis, contact dermatitis and psoriasis in both adults and children. It has a fairly good safety profile and is available as a cream, ointment, lotion, and as a foam under the tradename Verdeso Foam. Other trade names for creams, lotions, and ointments include Tridesilon, DesOwen, Desonate. It is a group VI corticosteroid under US classification, the second least potent group.
Classification
Small molecule
Drug classtopical steroids (acetal derivatives)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
Identifiers
PDB—
CAS-ID638-94-8
RxCUI—
ChEMBL IDCHEMBL1201109
ChEBI ID204734
PubChem CID12536
DrugBankDB01260
UNII IDJ280872D1O (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Desonide
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 433 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
55,332 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use